Recon: Eisai, Biogen nab FDA win for once-a-month Leqembi maintenance dose; Sage rejects $469M Biogen buyout

ReconReconApproval/marketing authorizationBiologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)